Aurora激酶及其抑制剂研究状态综述

Aurora激酶家族是苏氨酸/丝氨酸激酶,在有丝分裂的染色体排列,分离和胞质分裂中起重要作用。最近的研究发现,Aurora激酶在大量人类实体瘤和血液恶性肿瘤中过表达,表明其是开发抗肿瘤药物的重要靶点。本文就近几年国内外对Aurora激酶的研究,对Aurora激酶的生物学功能、与肿瘤的关系及其抑制剂的研究进展进行综述。     

肿瘤治疗靶向药物Aurora激酶抑制剂

Aurora激酶在肿瘤细胞的有丝分裂进程中起着重要的调控作用,从而影响细胞周期进程,是抗肿瘤药物的新靶点。本文就Aurora激酶在肿瘤细胞生长中所起的作用及现阶段的Aurora激酶抑制剂进行系统介绍。     

Aurora激酶及其抑制剂研究进展

Aurora激酶的三种亚型Aurora-A、Aurora-B、Aurora-C是细胞有丝分裂的重要调节因子,近年来成为癌症治疗的热门靶点.本文重点介绍Aurora激酶三种亚型与肿瘤的关系,以及Aurora激酶抑制剂的最新研究进展和研究方向.     

Aurora激酶及其抑制剂的研究进展

恶性肿瘤是威胁人类生命健康的重大难治性疾病,人类在恶性肿瘤的治疗过程中经历了漫长的历史变迁。Aurora激酶家族是苏氨酸/丝氨酸激酶,是细胞有丝分裂期重要的调节因子,可影响细胞周期进程,是抗肿瘤药物的新靶点。本文简要对Aurora激酶的生物学功能、与肿瘤的关系及其抑制剂的研究进展进行综述。     

Aurora激酶及其抑制剂的研究进展

目的 从结构出发介绍Aurora激酶及其抑制剂的研究进展。方法 总结 Aurora激酶抑制剂骨架特征和结合模式,以及进入临床的Aurora激酶抑制剂的研究进展。结果和结论 Aurora激酶家族是肿瘤治疗的一个新兴靶标。腺嘌呤骨架可能是设计高活性Aurora激酶抑制剂的重要母核。     

Aurora激酶抑制剂的研究进展

在有丝分裂的过程中,Aurora激酶参与纺锤体形成,中心体成熟,染色体分化和胞质分裂.Aurora激酶的过度表达或分化易导致有丝分裂异常,与形成肿瘤的基因组不稳定性密切相关.以Aurora激酶为靶点设计、合成的药物已成为近年来肿瘤药物治疗的研究热点.本文综述了已经进入临床研究的Aurora小分子抑制剂在临床前、临床的研究进展.     

Aurora激酶抑制药研究进展

Aurora激酶是近年来发现的新型抗肿瘤靶点,它在肿瘤的发生发展中起到至关重要的作用。该文从Aurora激酶作为抗肿瘤靶点的意义,Aurora-A激酶特异性抑制药及临床应用,Aurora-B激酶特异性抑制药及临床应用,Pan-Aurora激酶特异性抑制药及临床应用等几个方面,对Aurora激酶抑制药的研究进展进行论述,期望能够对临床工作者有所帮助。     

Aurora激酶抑制剂研究进展

Aurora激酶家族是细胞有丝分裂期重要的调节因子,可影响细胞周期进程,是抗肿瘤药物的新靶点。简述Aurora激酶的生物学和与肿瘤发生发展的关系,重点介绍Aurora激酶抑制剂的结构类型和构效关系。     

Aurora激酶抑制剂的结构优化策略

Aurora激酶是一种丝氨酸/苏氨酸蛋白激酶,在肿瘤细胞的有丝分裂进程中起着重要的调控作用。因此,以该激酶为靶点,开发新型抗肿瘤药物,已成为研究热点。从提高化合物的活性和选择性、增加其水溶性及改善其药动学性质等方面,综述Aurora激酶抑制剂的结构优化策略。     

RNA干扰Aurora A表达对人子宫内膜癌细胞的生长与细胞周期的影响

目的 探讨应用RNA干扰技术抑制Aurora A基因表达,并研究Aurora A基因表达下调对人子宫内膜癌细胞生长和细胞周期分布的影响.方法 用RNA干扰法抑制Aurora A的蛋白表达,RT-PCR及Western blot方法 检测Aurora A mRNA和蛋白表达,流式细胞仪检测细胞周期分布的变化,四氮唑盐法(MTT)检测转染前后细胞生长抑制率变化.结果 siRNA Aurora A可明显降低Aurora A mRNA和蛋白的表达,siRNA Aurora A导入Ishikawa细胞48 h后,细胞的生长被抑制,细胞周期阻滞于G2/M期和S期;细胞的凋亡率明显升高.结论下调AuroraA表达可抑制人子宫内膜癌细胞系Ishikawa的增殖,同时导致细胞阻滞于G2/M期及S期并且促进细胞凋亡.     

A small molecule identified through an in silico screen inhibits Aurora B–INCENP interaction

Aurora B is a serine/threonine kinase that has a central role in the regulation of mitosis. The observation of Aurora B overexpression in cancer makes it a promising target to develop antitumoral inhibitors. We describe a new potential inhibitor that exclusively targets the interaction site of Aurora B and its activator INCENP. We performed a structure‐based virtual screening and determined five potential candidates of 200 000 compounds, which selectively bind to the Aurora B::INCENP interaction site, but not to the ATP‐binding site (kinase pocket) of Aurora B or other related kinases. Further characterization in vivo validated the inhibitory role of one of these five compounds in Aurora B::INCENP complex formation and exhibited hallmarks of Aurora inhibition such as chromosome congression and segregation defects that interfere with the progression into cytokinesis and result in multinuclear cells. Our results provide an alternative approach on the way of exploring specific kinase inhibitors.     

A Dual Non‐ATP Analogue Inhibitor of Aurora Kinases A and B,Derived from Resorcinol with a Mixed Mode of Inhibition

Aurora kinases are the most commonly targeted mitotic kinases in the intervention of cancer progression. Here, we report a resorcinol derivative, 5‐methyl‐4‐(2‐thiazolylazo) resorcinol (PTK66), a dual inhibitor of Aurora A and Aurora B kinases. PTK66 is a surface binding non‐ATP analogue inhibitor that shows a mixed pattern of inhibition against both of Aurora A and B kinases. The in vitro IC₅₀ is approximately 47 and 40 μm for Aurora A and Aurora B kinases, respectively. In cellular systems, PTK66 exhibits a substantially low cytotoxicity at micromolar concentrations but it can induce aneuploidy under similar dosages as a consequence of Aurora kinase inhibition. This result was corroborated by a drop in the histone H3 (S10) phosphorylation level detected via Western blot analysis using three different cell types. Altogether, our findings indicate that the ligand containing resorcinol backbone is one of the novel scaffolds targeting the Aurora family of kinases, which could be a target for antineoplastic drug development.     

An update on the pharmacokinetics and pharmacodynamics of alisertib,a selective Aurora kinase A inhibitor

Human Aurora kinases, including Aurora kinase A (AURKA), B (AURKB), and C (AURKC), play an essential role in mitotic events such as monitoring of the mitotic checkpoint, creation of bipolar mitotic spindle and alignment of centrosomes on it, also regulating centrosome separation, bio‐orientation of chromosomes and cytokinesis. AURKA and AURKB are key regulators of mitosis and centrosome via polymerizing microfilaments and controlling chromatid segregation. In particular, AURKA plays critical roles in the regulation of mitotic entry, centrosome function, bipolar spindle assembly, and chromosome segregation. AURKA has been found to be overexpressed in various solid and haematological cancers and has been linked with poor prognosis. Its important role in cancer initiation, growth, and metastasis has brought the focus to search for potent and selective AURKA inhibitors for cancer treatment. MLN8237, also known as alisertib, is one selective AURKA inhibitor that has shown remarkable anticancer effects in preclinical studies. Alisertib exhibits favourable pharmacokinetic properties. Alisertib has generally showed good partial response rates of 4–52% and good safety profiles in Phase I and II trials when it is solely administered as well as combined with cytotoxic chemotherapeutic drugs. Recently, the multicentre, randomized Phase III study of alisertib in patients with relapsed or refractory peripheral T‐cell lymphoma has been discontinued due to unsatisfactory efficacy. The low risk of side effects, accessibility, and effectiveness of alisertib makes it a new promising anticancer therapy and further mechanistic and clinical studies are warranted.